Oryzon Genomics SA (ORYZF)
3.31
0.00 (0.00%)
USD |
OTCM |
Sep 25, 16:00
Oryzon Genomics Research and Development Expense (TTM) : 20.67M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 20.67M |
| March 31, 2026 | 17.15M |
| December 31, 2025 | |
| September 30, 2025 | |
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 |
| Date | Value |
|---|---|
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| September 30, 2021 | 11.69M |
| June 30, 2021 | 8.123M |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | 4.906M |
| December 31, 2019 | 3.442M |
| September 30, 2019 | 5.468M |
| June 30, 2019 | 7.155M |
| March 31, 2019 | 9.031M |
| December 31, 2018 | 8.754M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Pharma Mar SA | 110.74M |
| Grifols SA | 477.82M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alkermes Plc | 384.84M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |